Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-LUNG)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04676386 |
Recruitment Status :
Suspended
(Assessment for recruitment futility)
First Posted : December 21, 2020
Last Update Posted : January 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
NSCLC Stage IV NSCLC, Stage IIIC | Diagnostic Test: Primary Immune Response (PIR) test by Biodesix, Inc. |
This is an observational, multicenter study designed to assess biomarkers (serum and plasma) as predictive of early progression in 390 treatment-naive patients with advanced stage non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥50% treated with two standard of care (SOC) regimens, platinum based PD-1/PD-L1 regimen with monotherapy (single agent PD-1/PD-L1 therapy).
Prior to enrollment, tumor specimens will be tested for PD-L1 expression according to participating centers' standard operating procedures. Patients will be treated, according to physician choice, with platinum-based PD-1/PD-L1 regimen versus single agent PD-1/PD-L1 regimen. For each treatment cohort of 195 patients, enrollment will proceed in sub-cohorts to ensure a population with 20% ECOG PS2 patients and a total of 40 squamous cell carcinoma patients per treatment arm.
Patients will receive one of the following standard-of-care (SOC) treatment regimens at the discretion of the treating investigator:
- PD-1/PD-L1 therapy
- Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
Tumor assessment will follow RECIST v1.1.
Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
Remaining serum and plasma will be stored for subsequent exploratory studies and will be available to the investigators in the ALCMI network per ALCMI standard operating procedures.
Additionally, pathology reports including PD-L1 results and Next Generation Sequencing results, from any CLIA laboratory, will be collected.
Study Type : | Observational |
Estimated Enrollment : | 390 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy |
Actual Study Start Date : | February 1, 2021 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | December 2023 |
Group/Cohort | Intervention/treatment |
---|---|
PD1/PD-L1
Standard of Care: PD1/PD-L1 monotherapy
|
Diagnostic Test: Primary Immune Response (PIR) test by Biodesix, Inc.
Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively. |
PD1/PD-L1 + chemo
Standard of Care: Platinum doublet-based chemotherapy plus PD-1/PD-L1 combination
|
Diagnostic Test: Primary Immune Response (PIR) test by Biodesix, Inc.
Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively. |
- Biomarker PIR evaluation [ Time Frame: 3 years ]To collect biospecimens and evaluate candidate biomarkers of early progression on patients with >50% PD-L1 positive tumors treated with PD-1/PD-L1 monotherapy or PD-1/PD-L1/chemotherapy combination
Biospecimen Retention: Samples With DNA
A maximum of three blood draws will be performed over three years.
Approximately 25 mLs venous blood will be collected into blood collection tubes provided in the study kit. Blood should be drawn at the time of other clinical laboratories whenever possible to prevent additional venipuncture or port access, otherwise, a study-specific blood draw may occur at the time of the standard of care office visit.
Peripheral blood draws may occur on-site or via a remote phlebotomist dispatched by the enrolling institution. Sites may mail the blood draw kit to the subject prior to arrival of the remote phlebotomist.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Treatment naïve for their stage IIIC/IV AJCC 8 non-small cell lung cancer with a tumor biopsy PD-L1 TPS > 50%
- Intent to treat with PD-1/PD-L1 or PD-1/PD-L1 plus pemetrexed/carboplatin or paclitaxel/nab-paclitaxel/carboplatin
- ECOG PS 0-2
- Ability to consent to participate in the study
Exclusion Criteria:
- Ability to understand the requirements of the protocol or to provide informed consent is impaired or is unwilling to comply with the protocol requirements

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04676386
United States, California | |
Addario Lung Cancer Medical Institute (ALCMI) | |
San Carlos, California, United States, 94070 | |
United States, Illinois | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 |
Responsible Party: | Addario Lung Cancer Medical Institute |
ClinicalTrials.gov Identifier: | NCT04676386 |
Other Study ID Numbers: |
ALCMI-014 |
First Posted: | December 21, 2020 Key Record Dates |
Last Update Posted: | January 27, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |